Method of identifying hormone antagonists and agonists

• US 5,759,785 A
• Filed: 05/23/1995
• Issued: 06/02/1998
• Est. Priority Date: 05/14/1992
• Status: Expired due to Fees

• Current Assignee: Baylor College of Medicine (Baylor College)
• Original Assignee: Baylor College of Medicine (Baylor College)
• Inventors: Tsai, Sophia Yang, Allan, George Francis, Tsai, Ming-Jer, O'Malley, Bert W.
• Primary Examiner(s): Green, Lora M.
• Application Number:
  US08/448,270
• Time in Patent Office: 1,106 Days
• Field of Search: 435/6, 435/7.1, 435/7.2, 435/7.21, 435/23, 435/24, 436/501, 436/503, 436/536, 436/174, 436/175, 436/177, 436/178, 436/817
• US Class Current: 435/7.1
• CPC Class Codes: G01N 33/743 Steroid hormones
• CPC Class Codes: Y10S 436/817 Steroids or hormones
• CPC Class Codes: Y10T 436/25 including sample preparation
• CPC Class Codes: Y10T 436/25125 Digestion or removing interfering materials

Abstract

The present invention provides a novel method of determining the antagonist and agonist activity of a compound for steroid hormone receptors. The present invention also provides a method of determining antagonist activity of a compound for a hormone receptor by inducing the conformational change in the receptor. In addition, the present invention provides a novel method of determining the level of agonist activity of a compound for steroid hormone receptors.

Claims

1. A method of determining antagonist activity of a compound for a hormone receptor of the steroid hormone superfamily, comprising the steps of:

combining said compound with said hormone receptor in vitro so as to induce a conformational change in said receptor, and

digesting said receptor with a proteolytic enzyme to detect said conformational change in said receptor, thereby measuring whether said compound is an antagonist of said receptor wherein the agonist-receptor fragment produced by the method is always greater than the antagonist receptor fragment.

2. The method of claim 1, wherein said hormone receptor is selected from the group consisting of estrogen, glucocorticoid, mineralocorticoid, androgen, thyroid hormone, retinoic acid, retinoid X, Vitamin D3, testosterone and orphan receptors.

3. The method of claim 1 wherein the proteolytic fragments of said receptor are separated by electrophoresis in a denaturing gel.

4. The method of claim 1, wherein said proteolytic enzymes are selected from the group consisting of trypsin, V8, chymotrypsin and subtilisin.

5. The method of claim 1, wherein said conformational change is in the carboxy terminus of the receptor.

6. The method of claim 1 wherein the agonist-receptor fragment is always 30 kDa or greater and the antagonist-receptor fragment is always less than 30 kDa.